Metformin/Empagliflozin and Dolutegravir Interaction
Drug interaction information between Metformin/Empagliflozin and Dolutegravir.
Metformin/Empagliflozin and Dolutegravir have a documented moderate interaction in FDA labeling.
FDA drug labeling documents a moderate-severity interaction between Metformin/Empagliflozin and Dolutegravir. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.
How They Interact
Dolutegravir blocks the specific pumps in the kidneys that remove metformin from the body. This can cause metformin levels to rise, increasing the risk of a dangerous acid buildup.
FDA Label Information
Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .
Metformin/Empagliflozin Also Interacts With
- Metformin moderate
- Ranolazine moderate
- Cimetidine moderate
- Empagliflozin moderate
- Topiramate minor
Dolutegravir Also Interacts With
- Dofetilide major
- Empagliflozin moderate
- Empagliflozin/Linagliptin moderate
- Ertugliflozin moderate
- Linagliptin moderate
Frequently Asked Questions
What SPL severity band is on file for Metformin/Empagliflozin + Dolutegravir?
Compiled FDA labeling labels this pair moderate. That is a source-record field, not an individual medication-combination decision.
Which drug in this pair has the larger labeled-interaction portfolio?
Dolutegravir has 28 labeled pairs on file vs Metformin/Empagliflozin's 9. In the moderate band specifically: Metformin/Empagliflozin has 5 (also Metformin, Ranolazine, Cimetidine, Empagliflozin); Dolutegravir has 6 (also Empagliflozin, Empagliflozin/Linagliptin, Ertugliflozin, Linagliptin).
What mechanism field is on file for Metformin/Empagliflozin and Dolutegravir?
Dolutegravir blocks the specific pumps in the kidneys that remove metformin from the body. This can cause metformin levels to rise, increasing the risk of a dangerous acid buildup.
Dolutegravir carries more major-labeled pairs than Metformin/Empagliflozin
SPL source-record counts only. This page's band is moderate · classes on file: Metformin/Empagliflozin (Biguanide / SGLT2 Combination); Dolutegravir (Integrase Strand Transfer Inhibitor).
Dolutegravir has 1 major-labeled pair vs Metformin/Empagliflozin's 0. This page itself is in the moderate band, not the major band.
0 major · 5 moderate · 4 minor · 9 total
- Other moderate peers for Metformin/Empagliflozin
- Metformin
- Ranolazine
- Cimetidine
- Empagliflozin
1 major · 6 moderate · 21 minor · 28 total
- Other moderate peers for Dolutegravir
- Empagliflozin
- Empagliflozin/Linagliptin
- Ertugliflozin
- Linagliptin
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.
Read our methodology - how this data is sourced, computed, and verified.